The current financial score of Harvard Bioscience Inc is 6.34. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 22.20M, representing a year-over-year increase of 7.79%, while its net profit experienced a year-over-year increase of 113.08%.
The current valuation score of Harvard Bioscience Inc is 8.42. Its current P/E ratio is -4.42, which is -95.13% below the recent high of -0.22 and -2794.62% above the recent low of -128.07.
The current earnings forecast score of Harvard Bioscience Inc is 7.00. The average price target is 10.25, with a high of 13.00 and a low of 7.50.
The current price momentum score of Harvard Bioscience Inc is 4.72. Currently, the stock price is trading between the resistance level at 10.43 and the support level at 8.13, making it suitable for range-bound swing trading.
The current institutional shareholding score of Harvard Bioscience Inc is 5.00. The latest institutional shareholding proportion is 54.17%, representing a quarter-over-quarter increase of 13.62%.
The current risk assessment score of Harvard Bioscience Inc is 4.05. The company's beta value is 1.55. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.